Year archive

ERYTECH Pharma S.A. — 2024 filings

All 55 regulatory filings released by ERYTECH Pharma S.A. (ERYP) in 2024, sourced directly from the official regulator.

55 Filings

2024 Period

2024 filings (55)

Filing	Released	Lang
Inside Information / Other news releases Earnings Release Q4 2024	2024-12-30	English
Informations privilégiées / Autres communiqués Earnings Release FY 2024	2024-12-30	French
PHAXIAM Therapeutics : information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 novembre 2024 Declaration of Voting Results & Voting Rights Announcements	2024-12-05	French
PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-12-05	English
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area Investor Presentation	2024-11-27	English
PHAXIAM présente une stratégie de développement ambitieuse pour tirer parti de l'évolution rapide du marché de la phagothérapie Earnings Release FY 2024	2024-11-27	French
PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day » Regulatory Filings	2024-11-18	French
PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" Regulatory Filings	2024-11-18	English
PHAXIAM Reports Third-Quarter 2024 Financial Information Earnings Release Q3 2024	2024-11-13	English
PHAXIAM publie l’information financière du troisième trimestre 2024 Earnings Release Q3 2024	2024-11-13	French
Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-11-08	English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024 Declaration of Voting Results & Voting Rights Announcements	2024-11-08	French
PHAXIAM Therapeutics obtient l’autorisation de la FDA américaine pour lancer l’étude de phase II GLORIA aux Etats-Unis Earnings Release Q4 2024	2024-11-04	French
PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S. Regulatory Filings	2024-11-04	English
Monthly information related to total number of voting rights and shares composing the share capital – October 8, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-10-10	English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 8 octobre 2024 Declaration of Voting Results & Voting Rights Announcements	2024-10-10	French
PHAXIAM Therapeutics annonce la validation d’une nouvelle étude de phase 2, PHAGOSCARPA, sponsorisée par un investigateur Regulatory Filings	2024-10-09	French
PHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study Regulatory Filings	2024-10-09	English
PHAXIAM fait le point sur ses activités et publie ses résultats financiers du premier semestre 2024 Earnings Release H1 2024	2024-09-25	French
PHAXIAM Provides Business and Financial Update For the First Half of 2024 Interim / Quarterly Report H1 2024	2024-09-25	English
PHAXIAM : RAPPORT FINANCIER SEMESTRIEL Interim / Quarterly Report H1 2024	2024-09-25	French
Franchissement de seuils et déclaration d'intention Major Shareholding Notification	2024-07-04	French
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 1er juillet 2024 Declaration of Voting Results & Voting Rights Announcements	2024-07-03	French
Monthly information related to total number of voting rights and shares composing the share capital – July 1, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-07-03	English
Results of the Combined General Meeting of 28 June 2024 AGM Information	2024-06-28	English
Résultats de l'Assemblée Générale Mixte du 28 juin 2024 AGM Information	2024-06-28	French
PHAXIAM Therapeutics annonce le succès de son augmentation de capital avec maintien du droit préférentiel de souscription de 7,8 M€ Share Issue/Capital Change	2024-06-27	French
Lancement d'une augmentation de capital avec maintien du DPS d’un montant d’environ 10 M€, susceptible d’être porté à environ 11,5 M€ en cas d’exercice intégral de la clause d'extension Capital/Financing Update	2024-06-12	French
PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024 AGM Information	2024-06-07	English
PHAXIAM annonce les modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 28 juin 2024 AGM Information	2024-06-07	French
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 mai 2024 Declaration of Voting Results & Voting Rights Announcements	2024-06-05	French
Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-06-05	English
PHAXIAM provides Business and Financial Update for the First Quarter of 2024 Earnings Release Q1 2024	2024-05-15	English
PHAXIAM Therapeutics fait le point sur ses activités et publie l’information financière du premier trimestre 2024 Earnings Release Q1 2024	2024-05-15	French
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2024 Declaration of Voting Results & Voting Rights Announcements	2024-05-03	French
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-05-03	English
PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus Regulatory Filings	2024-04-15	English
PHAXIAM Therapeutics annonce le recrutement du premier patient dans l’étude de phase 1 dans l’endocardite infectieuse causée par le Staphylococcus aureus Earnings Release Q2 2024	2024-04-15	French
Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-04-09	English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 mars 2024 Declaration of Voting Results & Voting Rights Announcements	2024-04-09	French
PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD) Report Publication Announcement	2024-04-05	English
PHAXIAM Therapeutics annonce le dépôt de son Document d’Enregistrement Universel (URD) 2023 Report Publication Announcement	2024-04-05	French
Document d'Enregistrement Universel 2023 Annual Report (ESEF) FY 2023	2024-04-05	French
PHAXIAM Therapeutics publie ses résultats annuels 2023 et fait le point sur ses activités Earnings Release FY 2023	2024-03-20	French
PHAXIAM Announces 2023 Full-Year Results and Provides Business Update Earnings Release FY 2023	2024-03-20	English
Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024 Share Issue/Capital Change	2024-03-05	English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 février 2024 Share Issue/Capital Change	2024-03-05	French
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market Delisting Announcement	2024-02-20	English
PHAXIAM Therapeutics annonce son intention de procéder au retrait volontaire de ses « American Depositary Shares » du Nasdaq Capital Market Delisting Announcement	2024-02-20	French
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 janvier 2024 Declaration of Voting Results & Voting Rights Announcements	2024-02-06	French
Monthly information related to total number of voting rights and shares composing the share capital - January 31, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-02-06	English
PHAXIAM Therapeutics annonce son niveau de trésorerie à fin 2023 et son calendrier financier 2024 Capital/Financing Update	2024-01-18	French
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024 Report Publication Announcement	2024-01-18	English
Monthly information related to total number of voting rights and shares composing the share capital - December 31, 2023 Declaration of Voting Results & Voting Rights Announcements	2024-01-03	English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2023 Declaration of Voting Results & Voting Rights Announcements	2024-01-03	French

Filings by year

2025 28 filings
2024 55 filings
2023 102 filings
2022 57 filings
2021 118 filings
2020 57 filings
2019 63 filings
2018 45 filings
2017 89 filings
2016 72 filings
2015 86 filings
2014 70 filings
2013 22 filings